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Case presentation
A 62-year-old woman was admitted to New England Medical
Center Hospital (NEMCH) for evaluation of chronic renal fail-
ure. The patient's history included rheumatic fever at age 13, two
myocardial infarctions 5 and 3 years earlier, hypertension for 20
years, congestive heart failure for 2 to 3 years, and adult-onset
diabetes mellitus. Ten years prior to admission, she presented
with blurred vision and a blood sugar concentration of 640 mg/
100 ml. She was treated with insulin but developed hives. The
diabetes was well controlled, however, through oral hypogly-
cemic agents and a diet of 1,400 calories per day. She had no
history of diabetic retinopathy, neuropathy, or peripheral vascu-
lar disease. At age 42, a heart murmur was first noted, and the
patient began a regimen of digitalis. She had one urinary tract
infection approximately 10 years prior to admission. The blood
urea nitrogen (BUN) concentration was 40 mg/l00 ml 2 years
prior to admission.
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During the few months prior to admission, the patient de-
scribed numerous episodes of chest pain radiating to the right
arm and relieved by nitroglycerin. Two weeks prior to admis-
sion, she was admitted to another hospital for lethargy and ano-
rexia. Examination revealed a BUN concentration of 160 mg/100
ml. She was transferred to NEMCH.
On admission, the physical examination revealed the follow-
ing: blood pressure, 190/90 mm Hg; pulse, 70/mm and regular;
respirations, 16/mm; temperature, 37°C; weight, 50.6 kg; no
hemorrhages, exudates, or diabetic microaneurysms of the optic
fundi; the chest was clear to percussion and auscultation. Car-
diac examination revealed the following: regular rhythm; a
Grade tl/Vl systolic ejection murmur at the upper left sternal
border radiating to both carotid arteries; peripheral edema, I +;
no pericardial friction rub. The remainder of the examination
was unremarkable.
Laboratory findings revealed the following data: hematocrit,
23%; hemoglobin, 7 g/l00 ml; white blood cell count, 10,700/mm:3
with a normal differential; serum sodium. 123 mEq; serum potas-
sium, 4.3 mEq; serum chloride, 90 mEq; total serum carbon
dioxide, 17 mEq/liter; BUN, 99 mg; serum creatinine, 10.3 mg;
serum calcium, 7.4 mg; serum phosphorus, 8.5 mg; serum albu-
min, 3.2 g1100 ml. Results of urinalysis revealed: pH, 6; specific
gravity, 1.012; 0 to 3 white blood cells and 0 to 1 red blood cells
per high power field; protein, 1 +. Twenty-four-hour urine pro-
tein excretion was 2.7 g. Several urine cultures were sterile. A
chest radiogram revealed cardiomegaly with engorged pulmo-
nary vasculature. An echocardiogram revealed calcification of
the mitral valve and evidence of mitral stenosis. An elec-
trocardiogram (EKG) revealed a sinus rhythm of 80 beats per
minute, inverted T waves in leads 1, 2, V5 and V6, and voltage
criteria for left ventricular hypertrophy. An i.v. urogram re-
vealed bilaterally small kidneys. An echogram of the kidney, ure-
ters, and bladder revealed no evidence of post-void residual or
obstruction.
The patient's uremia and congestive heart failure responded to
treatment with diuretics and dietary protein and sodium restric-
tion. An arteriovenous fistula was created for future use. Five
months after the first hospitalization, hemodialysis was attempt-
ed to relieve recurring nausea and vomiting. Either a 1.0 or 0.6
m2 coil dialyzer was used with an average blood how of 140 cc!
mm. Four of five dialyses, however, were complicated by se-
vere hypotension, chest pain, nausea, and vomiting thought to be
attributable to poor myocardial function. Typically, the blood
pressure fell as low as 50/0 mm Hg either at the beginning or
within 1 hour of the beginning of dialysis. The patient frequently
converted to atrial fibrillation (pulse, 100 to 1 10/mm) during the
periods of hypotension. Acetate was used as the source of al-
kalai, and the hematocrit was maintained above 25%. Because of
the severe hypotension and angina during hemodialysis, the use
of the artificial kidney was discontinued and the patient was
treated with a low protein (20 g/day) and a low sodium diet.
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The patient responded to conservative management with die-
tary manipulation alone until uremia recurred 6 months later
(BUN, 150 mg; serum creatinine, 11 mgJlOO ml). Hemodialysis
was again attempted. Over the next 10 months, the patient was
hemodialyzed three times per week, for 3.5 to 4 hours each time,
with a 1.3 m2 hollow fiber dialyzer. The patient had to be hospi-
talized on several occasions because of chest pain, hypotension,
atrial fibrillation, and ischemic changes noted on EKG during
hemodialysis. Attempts to remove excess fluid during dialysis
resulted in hypotension.
After 10 months of hemodialysis, the patient was transferred
to another hospital for peritoneal dialysis. A permanent perito-
neal catheter was placed in the left lower quadrant. Peritoneal
dialysis, using a conventional bottle-hanging" system, was per-
formed three times per week, for 10 hours each time, over the
next 6 months. A 1.5% glucose dialysate supplemented by 4.25%
hypertonic dialysate was used for each dialysis. Although the pa-
tient had one episode of chest pain lasting 2 hours with no eleva-
tion of cardiac enzymes, the chest pain and hypotension did not
recur in subsequent dialyses. Urine volume was less than 300 cc!
day. Medications included nitroglycerin, propranolol (40 mg,
four times daily), furosemide (800 mg/day), and digoxin (0.125
mg/day, 5 days per week).
During her first month of peritoneal dialysis as art out-patient,
episodes of abdominal pain and signs of a peritoneal inflamma-
tory reaction were present, but cultures were negative. A new
Tenckhoff catheter was placed in the right lower quadrant, and it
functioned well for the next 2 months. Blood pressures were in
the range of 120 to 130/70 to 80 mm Hg both before and after
dialysis. During this period, the patient's coronary artery disease
stabilized, and she was symptom-free and ambulatory at home.
At the beginning of the fourth month of pentoneal dialysis, the
patient developed tenderness over the catheter site, and cepha-
lexin in a dosage of 250 mg, four times daily, was given for 7
days. Pain persisted, however, in the lower quadrant and back;
abdominal plain film and echogram were unrevealing. The symp-
toms subsided briefly but then recurred with severe lower ab-
dominal pain, right lower quadrant tenderness, diarrhea, and
cramps. A radiogram revealed the catheter to be in the pelvic
area. Because the catheter was thought to be responsible for the
pain, it was retracted. Seven days later, diffuse abdominal pain
and signs of peritoneal inflammation recurred, and a cloudy
dialysate solution was noted. The patient was examined for pos-
sible bowel perforation associated with surgical manipulation of
the catheter. Dialysate cultures grew E. coli and diphtheroids
that were sensitive to cephalosporins, and cefazolin was pre-
scribed in a dosage of 0.5 g, three times daily. The patient contin-
ued to have lower abdominal pain, and findings were consistent
with peritoneal irritation in the right lower quadrant. Pelvic and
rectal examinations revealed pelvic inflammatory disease near
the right adnexae. An abdominal echogram was consistent with
an abscess in the area of the peritoneal catheter. The catheter
was removed surgically, and the patient was given a 2 week
course of antibiotics, which resulted in marked improvement.
With the onset of peritonitis, peritoneal dialysis was discontin-
ued, and hemodialysis was resumed through an existing left fore-
arm fistula. The patient tolerated hemodialysis (1.3 m2 hollow
fiber dialyzer) well for several months with no significant hypo-
tensive episodes. Laboratory findings before and after 6 months
of peritoneal dialysis were the following: hematocrit, 30% and
26%; serum albumin, 5.7 g and 3.2 g; BUN, 120 mg and 50 mg;
serum creatinine, 10 mg and 13 mg/100 ml. After 6 months of
peritoneal dialysis, an echocardiogram revealed that the pa-
tient's cardiac ejection fraction had increased from 40 to 60%.
Discussion
DR. KARL D. NOLPH (Director, Division of Ne-
phrology, University of Missouri Medical Center):
This 62-year-old woman with diabetes mellitus and
two previous myocardial infarctions was trans-
ferred to NEMCH with angina, lethargy, malaise,
anorexia, and a BUN concentration of 160 mg/100
ml. These findings coupled with physical and labo-
ratory findings obtained on admission indicated ure-
mia perhaps secondary to end-stage diabetic ne-
phropathy and congestive heart failure secondary to
atherosclerotic coronary artery disease. There was
evidence for rheumatic heart disease as well. Fol-
lowing a transiently successful trial of conservative
medical management, recurring nausea and vomit-
ing were noted. Extracorporeal hemodialysis was
initiated, but four of the first five hemodialyses were
complicated by severe hypotension associated with
angina. It is of interest that these episodes usually
occurred within the first hour of dialysis. Con-
servative management was attempted again, but
chronic hemodialysis had to be restarted when ure-
mic symptoms, such as fluid retention, weight gain,
and dyspnea, recurred between dialysis treatments.
Attempts to remove excess fluid during hemo-
dialysis frequently resulted in hypotension and re-
lated symptoms. After 10 months of this unsatisfac-
tory therapy, chronic peritoneal dialysis was
started. With easier fluid control, the patient did
well for several months, but then developed an in-
traperitoneal abscess that was refractory to antibi-
otic therapy until the catheter was removed. Hemo-
dialysis therapy was again started and this time she
tolerated it much better.
This patient's course will serve as the focal point
for our discussion today of chronic peritoneal dial-
ysis. The sequence of events in this patient high-
lights very nicely some of the relative advantages
and disadvantages of chronic peritoneal dialysis as
compared to chronic extracorporeal hemodialysis.
Chronic peritoneal dialysis and the problem pa-
tient. Chronic peritoneal dialysis is the treatment
often considered for patients who have unusual
problems with extracorporeal dialysis. In 1974,
Tenckhoff listed the following primary indications
for chronic peritoneal dialysis: (1) patients awaiting
transplantation and fistula maturation; (2) small
children; (3) older patients (60 years or older); (4)
patients with advanced cardiovascular disease; (5)
patients in whom reliable vascular access for hemo-
dialysis cannot be maintained; (6) patients for
whom hemodialysis is considered to be hazardous;
(7) patients who desire home dialysis but live alone;
(8) and patients who refuse blood transfusions [1].
More recently, particularly in Canada, chronic pen-
toneal dialysis has been advocated as a reasonable
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alternative to extracorporeal dialysis in most pa-
tients [2]. Hopefully, the new cooperative study
originated by the Veterans Administration will al-
low fair, well-controlled comparisons of peritoneal
dialysis and hemodialysis in large numbers of pa-
tients [3, 4]. This individual patient's problems,
however, offer the clinician insights into some cir-
cumstances in which chronic peritoneal dialysis of-
fers certain advantages. Let me review these specif-
ically as they relate to this patient.
Advantages of chronic peritoneal dialysis in dia-
betes (see Table 1). Chronic peritoneal dialysis has
been suggested in diabetes mellitus for several rea-
Sons [5]. In patients with widespread vascular dis-
ease, vascular access may be difficult to maintain,
although this did not seem to be a problem in our
patient. Problems are also evident with intermittent
extracorporeal dialysis in the repeated use of hepa-
nfl and the retinal ischemia associated with fluctua-
tions in blood pressure; both may accelerate diabet-
ic retinopathy and increase the risks of retinal hem-
orrhages [5, 6]. In contrast, stabilization of diabetic
retinopathy with chronic peritoneal dialysis has
been described [2, 5, 6]. Unfortunately, there are no
prospectively controlled studies to substantiate
these reports. It is an important question, however,
and needs to be addressed. It is noteworthy that this
patient had no evidence of diabetic retinopathy.
Since end-stage diabetic nephropathy is so often as-
sociated with diabetic retinopathy, the absence of
characteristic fundiscopic changes raises a question
about the cause of her end-stage renal disease.
Diabetes is frequently complicated by cardiovas-
cular disease; hypotension is less likely with perito-
neal dialysis than with hemodialysis in such pa-
tients. A most important problem in the manage-
ment of this patient was the repeated hypotensive
episodes during hemodialysis. Let us explore those
factors that can contribute to hypotension during
hemodialysis and then consider how peritoneal dial-
ysis may avoid many of these precipating mecha-
nisms.
Factors predisposing to hypotension during he-
,nodiaLvsis (see Table 2). In hemodialysis, patients
must tolerate a blood volume shift into the artificial
kidney. Even though dialysis machines are primed
with saline, the initial shift of blood to the dialyzer
may cause hypotension. The coil dialyzer initially
tried in this patient has a somewhat larger priming
volume than the hollow fiber dialyzers used later
[7]. Hypotension occurs less frequently with these
smaller volume dialyzers. During this patient's
first treatments hypotension occurred very early in
Table 1. Advantages and disadvantages of peritoneal dialysis in
diabetes
Advantages Disadvantages
No vascular access needed Poorer control of azotemia
Less risk to retinopathy Low clearances with advanced
disease
Less cardiovascular stress Obligate protein loss
Increased dialysis time
Glucose absorption
Infection
dialysis and may have been related to these initial
blood volume shifts.
Ultrafiltration takes place throughout dialysis at a
rate depending on transmembrane hydrostatic pres-
sure. With modern dialyzers, ultrafiltration rates
can be achieved that will precipitate hypotension in
almost any patient because plasma volume is con-
tracted more rapidly than extracellular fluid can be
mobilized to replace the ultrafiltrate. Prior to the
mobilization of extracellular fluid, reflex increases
in heart rate and increases in peripheral resistance
can help to prevent significant decreases in blood
pressure. In patients with autonomic insufficien-
cy—due to diabetes, for example—or underlying
cardiovascular disease, cardiovascular responses
may be inadequate and result in an increased sensi-
tivity to even low rates of ultrafiltration [8].
Recent evidence suggests that rapid decreases in
extracellular fluid osmolality with efficient large
surface dialyzers may increase the likelihood of
hypotension [9]. This complication may be due to
fluid shifts into the intracellular space and central
nervous system where osmolality decreases more
slowly. Bergstrom has recently reviewed evidence
obtained during isolated ultrafiltration—that is, ul-
trafiltration in the absence of flowing dialysate. Un-
der these circumstances many patients tolerate
more rapid rates of fluid removal without devel-
oping hypotension [9]. Simultaneous ultrafiltration
and dialysis seems to predispose patients to hypo-
tension. Tolerance to ultrafiltration during dialysis
can be improved with the administration of solutes
such as mannitol, which prevent rapid decreases in
extracellular fluid osmolality [10].
The rapid absorption of acetate during extra-
corporeal dialysis and the consequent increase in
serum acetate concentration may contribute to the
development of hypotension; bicarbonate loss may
also play a role [ii]. This patient was dialyzed
against a solution containing acetate. With efficient
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Table 2. Comparison of hypotensive mechanisms in
hemodialysis and peritoneal dialysis
Hemodialysis Peritoneal dialysis
Extracorporeal blood volume No extracorporeal blood
not tolerated distribution
Ultrafiltration rate often Ultrafiltration rates relatively
very high low
Rapid decreases in extracellular Low urea clearances, glucose
osmolality with high urea absorption, and hyponatric
clearances ultrafiltrates slow osmolality
changes
Acetate absorption and Low bicarbonate clearances
bicarbonate loss at rapid rates and slow acetate absorption
dialyzers, acetate absorption rates exceed acetate
metabolic rates, and measurable increases in serum
acetate are common. It is hypothesized that acetate
may contribute to a patient's intolerance to rapid
ultrafiltration by affecting the cardiovascular re-
sponse. Some preliminary studies indeed suggest
that patients tolerate ultrafiltration better when a bi-
carbonate containing bath is used [11]. Isolated ul-
trafiltration has the advantage of eliminating acetate
absorption during the process, which may explain
some of the beneficial effects.
Factors n inimizing hypotension during perito-
neal dialysis (see Table 2). Because the "blood-
path" of peritoneal dialysis is the peritoneal capil-
lary bed, there are no blood volume shifts during
peritoneal dialysis [12]. Unlike hemodialysis, ultra-
filtration occurs at a relatively slow rate. Even with
hypertonic 4.25% dextrose dialysis solutions, ultra-
filtration rates in excess of 10 mllmin are unusual
[13]. Still, hypotension can be induced during pen-
toneal dialysis, particularly with repeated use of hy-
pertonic exchanges, but it is generally easy to avoid
this complication by using the 4.25% dextrose solu-
tions only intermittently. With 1.5% dextrose solu-
tions net ultrafiltration rates are very low, usually
less than 3 mI/mm. In contrast, many of the extra-
corporeal dialyzers have much higher ultrafiltration
rates, even at low transmembrane pressures.
Urea is removed less rapidly during peritoneal
dialysis than during hemodialysis and thus extra-
cellular osmotic changes occur more slowly [13].
Decreases in BUN concentration are coupled with
glucose absorption—often approximately 15 and 40
glhr, respectively, when using hourly 1.5% and
4.25% dextrose exchanges [14]. As a result, serum
glucose concentration increases, thereby blunting
the decrease in extracellular osmolality. Also, the
electrolyte concentration of the net ultrafiltrate
formed during peritoneal dialysis is lower than the
electrolyte concentration of the extracellular fluid
[15—17].
Finally, if changes in serum acetate and bicarbo-
nate concentrations play a role in hypotension, it is
noteworthy that acetate absorption rates and bi-
carbonate removal rates are relatively slow in pen-
toneal dialysis compared to extracorporeal dialysis
[12], and that many peritoneal dialysis solutions
contain lactate rather than acetate.
Thus, there are many possible but mostly unprov-
en explanations for why hypotension is less likely to
develop during peritoneal dialysis compared to he-
modialysis. Most reports of these advantages re-
main anecdotal or hypothetical. Nevertheless, it is
widely accepted that hypotension can usually be
avoided in peritoneal dialysis. In this particular pa-
tient, hypotension might have been avoided during
hemodialysis by using isolated ultrafiltration, bi-
carbonate dialysate, or smaller dialyzers with less
surface area and lower priming volumes.
Disadvantages of chronic peritoneal dialysis in
diabetes (see Table 1). In intermittent peritoneal
dialysis, the serum concentrations of urea and
creatinine are usually less well controlled. In this
patient, BUN and creatinine concentrations were
higher during the period of penitoneal dialysis treat-
ments. She was treated, however, with only three
10-hour sessions per week. Many centers now rec-
ommend four 10-hour sessions per week and
achieve slightly better control of the blood chem-
istries [2, 13]. This recommendation remains empir-
ical because acceptable definitions of the adequacy
of dialysis remain elusive. If it is true that the major
uremic toxins are large molecular weight solutes,
then 30 hours of peritoneal dialysis per week should
achieve "middle molecule" removal rates com-
parable to or greater than most extracorporeal tech-
niques [18].
A possible problem with peritoneal dialysis in
some patients with diabetes mellitus and far-ad-
vanced vascular disease may be relatively low pen-
toneal clearances [19]. This is certainly not the case
in all patients with diabetes mellitus [5, 6]. We do
not know what the peritoneal clearances were in
this patient. Such measurements are helpful in de-
ciding the total weekly penitoneal dialysis require-
ment. Low clearances are not an absolute con-
traindication to chronic peritoneal dialysis in pa-
tients with diabetes. Even with very low
clearances, continuous ambulatory peritoneal dial-
ysis (CAPD) may be considered [20, 21]. There is
now a good clue to why clearances might be low in
702 Nephrology Forum
diabetes mellitus and other diseases involving small
vessels. Accumulating evidence suggests that the
status of the peritoneal microcirculation may be a
major determinant of both the effective peritoneal
area and peritoneal permeability [12, 22, 23]. Small
vessel disease of the peritoneum may decrease both
and explain the selective decreases that have been
reported in larger molecular weight solute clear-
ances [19].
Protein losses are a problem with chronic perito-
neal dialysis, especially during episodes of peritoni-
tis [2, 13]. As exemplified by this patient, serum al-
bumin concentration often is decreased. In the ab-
sence of infection, however, most patients can be
maintained in an acceptable state of nitrogen bal-
ance with an adequate protein intake [24, 25].
Another disadvantage of peritoneal dialysis in
this patient, as mentioned earlier, was the increase
in dialysis time to 30—and perhaps more appropri-
ately 40—hours per week. This is one of the main
drawbacks to chronic peritoneal dialysis. I am
hopeful that this disadvantage may be overcome in
the future with the use of CAPD; using the Oreo-
poulos bag, this technique may require only brief
interruptions of normal activities four times per day
[26]. I will say more about this in a moment. Never-
theless, in this patient, increased dialysis time was
required.
Since ultrafiltration during peritoneal dialysis is
dependent on the osmotic gradient created by glu-
cose in the dialysate, the patient with diabetes must
deal with the increased problems of glucose absorp-
tion. The problem can usually be controlled by in-
creasing insulin through the usual route or by using
intraperitoneal insulin, as reported by Rubin et al
[27].
The greatest problem with peritoneal dialysis,
again well exemplified by our patient, is infection.
Using automated closed systems, the incidence of
peritonitis in chronic peritoneal dialysis has been
reduced to very low levels in most centers; it should
be possible to keep the infection rate to less than 1%
of catheter connection-disconnection procedures
[2, 28]. Some patients who have problems with re-
curring infections develop intraperitoneal ab-
scesses. Gram-negative organisms are not the usual
cause of peritonitis, and when these organisms are
found it must raise, as in this patient, questions
about an intra-abdominal source. This patient was
appropriately examined for possible bowel per-
foration but none was found; she improved after the
catheter was removed. Some patients simply can-
not clear recurring or persistent peritonitis without
removal of the catheter; resistance to therapy in
such instances may be due to the presence of infect-
ed debris within the catheter or along the exit site.
In our center, gram-positive organisms account for
77% of infections. Gram-negative infections do oc-
cur in the absence of intra-abdominal disasters but
are infrequent—about 9% of all infections. Aseptic
peritonitis has also been relatively unusual—about
14% in our experience.
Contrary to common belief, there is evidence that
the incidence of peritonitis is not increased in pa-
tients with diabetes [27]. Thus, one might have con-
sidered returning this patient to chronic peritoneal
dialysis with a new catheter after a reasonable peri-
od of time.
There are many other potential complications of
peritoneal dialysis [13], but I have touched on those
particularly germane to this woman. Other con-
cerns include an increase in central venous pressure
[29], an increase in pulmonary pressure [30], bra-
dyarrhythmias [31], and a decrease in arterial oxy-
gen tension [32] with fluid instillation. These seem
minor, however, compared to the adverse hemo-
dynamic effects of hemodialysis. No long-term dif-
ferences in the degree of hyperlipidemia encoun-
tered during hemodialysis versus peritoneal dialysis
have been reported.
The return to hemodialysis. On returning to he-
modialysis, this patient seemed much improved and
tolerated the required degree of ultrafiltration with-
out hypotension. Her improved tolerance for hemo-
dialysis may have resulted from the several months
on peritoneal dialysis during which time better con-
trol of extracellular fluid volume could have permit-
ted her cardiac function to improve. An alternative
explanation is that the smaller priming volumes re-
quired by hollow fiber dialyzers were less stressful
to her circulation. Another possibility is that auto-
nomic neuropathy may have improved. This pa-
tient's course demonstrates very well the diffi-
culties in comparing peritoneal dialysis and extra-
corporeal dialysis even in the same patient. The
apparently better stability of her blood pressure
during peritoneal dialysis compared with the first
experience with extracorporeal dialysis is not a con-
sistent advantage if compared with the later treat-
ments with hollow fiber dialyzers. Clinical com-
parisons are fraught with problems of changes in pa-
tient status and modifications of extracorporeal
techniques, which may influence markedly the com-
parisons. The Veterans Administration cooperative
study hopes to establish more legitimate com-
parisons of peritoneal and extracorporeal dialysis
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by randomizing the techniques in good dialysis can-
didates [3]. There are many variables, however, and
interpretation of comparative data will be a chal-
lenge.
I have discussed the possible advantages of
switching to chronic peritoneal dialysis in this pa-
tient; most are hypothetical or anecdotal. Peritoneal
dialysis was carried out in this patient with less
hypotension. Persistent peritoneal infection led to a
return to extracorporeal dialysis; this time, hemo-
dialysis was better tolerated than previously. In
many patients, peritoneal dialysis offers a reason-
able alternative to circumvent problems with hemo-
dialysis. Peritoneal dialysis, however, has its own
disadvantages. The choice of technique in problem
patients at this time must be individualized and of-
ten determined by the circumstances of the mo-
ment.
Questions and Answers
DR. J. 1. HARRINGTON: Dr. Nolph, you indicated
that an increased acetate concentration could pre-
sent a problem by affecting cardiac output or cardiac
function during dialysis. It has been our experience
that significantly increased serum concentrations of
acetate are more common in patients who have
been dialyzed using a 2.5 m2 hollow fiber artificial
kidney. Although we don't have serum acetate val-
ues for this patient, it seems unlikely that she had
very high concentrations during the time she was
using the 1.0 or 0.6 m2 coil dialyzer. We did mea-
sure serum bicarbonate concentrations prior to
some of the hypotensive episodes and they were not
reduced significantly. Thus, I am not convinced that
hyperacetatemia was responsible for the hypoten-
sive episodes in this patient.
DR. K. D. NOLPH: I think your points are well
taken. Most of the studies that have shown signifi-
cant increases in serum acetate concentrations, de-
creases in serum bicarbonate concentrations, and
increases in the anion gap during dialysis have in-
volved the use of large surface area dialyzers.
Whether the serum acetate concentrations reached
are toxic to the cardiovascular system is not clear.
In some of the initial studies in dogs, the acetate
injected was shown to cause cardiovascular prob-
lems, but the doses used were enormous [33]. A
more recent study demonstrated that hypotension
could be induced in dogs by acetate infusion rates
comparable to those achieved during hemodialysis
[34]. 1 think increased serum acetate concentrations
are a problem with large surface area dialyzers and
serum concentrations should be monitored care-
fully in any patient who has unusual sensitivity to
small increases in the serum concentration of ace-
tate. I mentioned acetate for the sake of complete-
ness in listing all of the mechanisms that have been
proposed to explain hypotension during hemo-
dialysis. Hyperacetatemia is probably unlikely in
the patient we are discussing today.
DR. ELBERT TUTTLE (Professor of Medicine,
Emory University School of Medicine): This pa-
tient's difficulty with acute volume changes may
have been aggravated by autonomic nervous sys-
tem insufficiency. How do you assess autonomic
function in your patients?
DR. K. D. NOLPH: One can often get a clue at the
bedside about the presence of autonomic in-
sufficiency. If there is a substantial decrease in sys-
tolic blood pressure unaccompanied by a rapid
pulse rate, there is likely to be a problem in the car-
diovascular reflexes. A variety of maneuvers, such
as the Valsalva and the cold pressor test, can docu-
ment further the autonomic problems. It is a com-
mon problem not only in diabetes but in patients
with uremia from other causes [8].
DR. PAUL TESCHAN (Associate Professor of Med-
icine, Vanderbilt University School of Medicine): In
addition to the fact that patients acutely bleed blood
into the extracorporeal circuit, which is usually re-
placed only by saline during the first pass through
the dialyzer, do you think that the so-called "dy-
namic volume" of certain of the dialyzers—espe-
cially coils and loosely connected plate dialyzers—
can also play an important role in causing hypoten-
sion?
DR. K. D. NOLPH: The priming volume given for
most dialyzers is that associated with a fairly low
pressure. Yet, as the transmembrane pressure is in-
creased to achieve ultrafiltration, coil dialyzers in
particular expand enormously, volume becoming a
linear function of the pressure within the dialyzer.
The parallel plate and hollow fiber dialyzers, on the
other hand, have relatively fixed volumes. The hol-
low fiber dialyzers are especially noncompliant,
their fiber dimensions remaining almost unchanged
as the positive pressure within the fiber or the nega-
tive pressure outside the fiber is increased. In those
dialyzers that do expand as the transmembrane
pressure is increased, a deterioration in clearance
characteristics is evident; this is probably due to
membrane-masking, which occurs when the mem-
brane is pushed up against mesh supports. Although
extracorporeal volume can increase enormously in
certain coil dialyzers as transmembrane pressure is
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increased, hypotension occurred so soon after start-
ing the dialysis procedure in this patient that I as-
sume maximum transmembrane pressure had not
been approached and that hypotension occurred at
a fairly low pressure.
DR. J. T. HARRINGTON: It did.
DR. J. J. COHEN: Dr. Noiph, you mentioned loss
of protein as one of the potential disadvantages of
intermittent peritoneal dialysis. The range for pro-
tein loss has been estimated to be about 10 to 15 g
per dialysis session [25]. This rate of protein loss is
similar to that seen in patients with moderately se-
vere nephrotic syndrome accompanied by hypoal-
buminemia. Yet, hypoalbuminemia does not seem
to be an issue in most patients undergoing chronic
peritoneal dialysis. Is there an explanation for this
differing response to protein loss?
DR. K. D. NOLPH: In the nephrotic syndrome the
decrease in serum albumin concentration as a func-
tion of urinary protein loss is greater than with simi-
lar degrees of protein loss by other routes [35]. In
nephrosis the whole body catabolic rate for albumin
is increased [35]. Patients undergoing peritoneal
dialysis seem able to keep up with the protein loss
by ingesting adequate amounts of protein.
DR. J. J. COHEN: Is hypoalbuminemia during
chronic peritoneal dialysis more common in pa-
tients who had the nephrotic syndrome before pro-
gressing to end-stage renal disease.
DR. K. D. NOLPH: Not to my knowledge. As re-
nal disease progresses, urinary protein losses de-
crease with reductions in glomerular filtration rate
(GFR). Also, since the nephrotic kidney itself may
be the site of enhanced albumin catabolism [36]—
that is to say that filtered albumin is catabolized by
the tubules so that urinary protein losses are only a
fraction of the total albumin filtered—progressive
reductions in GFR and nephron mass also decrease
albumin catabolism.
DR. E. TUTTLE: Katz, Rosenfeld, and Sellers
[37], studied the filtration and catabolic reabsorp-
tion of albumin in the nephrotic syndrome. They
clearly showed that the filtered load of albumin in
this condition greatly exceeds the amount excreted,
the remainder being catabolized during passage
through the tubules.
DR. K. D. NOLPH: That is why in animal models
of the nephrotic syndrome, the high catabolic rate
for albumin decreases following nephrectomy [36].
We have no documentation, however, that this pa-
tient ever had the nephrotic syndrome, and, in fact,
I am doubtful that she had diabetic nephropathy.
I think there is considerable evidence to the con-
trary, such as kidney size and absence of retinopa-
thy.
DR. VICTOR POLLAK (Professor of Medicine,
University of Cincinnati Medical Center): What do
we know about the character of the protein losses in
patients undergoing chronic peritoneal dialysis?
How much of the loss is albumin, and what is the
molecular weight of the proteins being lost?
DR. K. D. NOLPH: Some high molecular weight
proteins are lost, but the predominant protein lost in
these patients is albumin. Very interesting studies
in patients with multiple myeloma have shown that
peritoneal dialysis can be used to remove myeloma
proteins, including high molecular weight myeloma
proteins [38]. Still, the major loss is albumin.
DR. J. J. COHEN: In view of the lesser efficiency
of peritoneal dialysis, at least for the removal of
some substances, do you want to comment on re-
cent techniques developed to increase blood flow to
the peritoneal microcirculation and consequently to
improve the efficiency of the technique?
DR. K. D. NOLPH: A number of techniques are
being evaluated but none has received widespread
acceptance at this time. We do know that intra-
peritoneal vasodilators can increase clearances and
are beneficial in those patients who have reduced
clearances, although those with very destructive
vascular disease may remain refractory. Increased
clearances also result in increased protein losses; to
date most of the maneuvers designed to increase
clearances with vasodilators do so primarily for sol-
utes in the high molecular weight range, such as
protein, not in the low molecular weight range.
These findings are presumably related to the small
number of capillaries involved in exchange and
membrane resistance due to fluid films [12]. The en-
tire surface area of the peritoneal membrane ap-
proaches that of the skin; the total effective pore
area, however, is probably less than 1%. The ef-
fective pore area is in the range of the pore area of
the intercellular channels, particularly the capillary
endothelial intercellular channels [12]. The perito-
neal vessels that are small enough to engage in ex-
change—some 10 or less in diameter—are largely
confined, at least in rats, to the visceral peritoneum
just as it begins to reflect over the intestine; it is at
this point that one can see a number of small
branches that could participate in exchange. Else-
where in the peritoneum one finds mainly conduit
vessels of 30 p. in diameter or more leading to vis-
ceral organs. Of the small arterioles that then
branch into capillaries, most probably branch into
five capillaries or more [23]. Studies suggest that in
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the nonvasodilated state only one of four capillaries
is perfused; the others are held in reserve [23]. It
appears to be the sphincter tone of the final arteriole
or the so-called precapillary sphincter that controls
perfusion into these reserve capillaries. Vasodila-
tors probably increase flow into perfused arterioles
but also dramatically increase the number of capil-
laries perfused [23]. The work of Renkin [39] also
suggests that those capillaries that open later in the
vasodilated state are more permeable and have a
larger mean spore" diameter than the ones that are
perfused in the nondilated state. This could explain
why those maneuvers that vasodilate might in-
crease selectively the clearances of the higher mo-
lecular weight solutes, thus, increasing protein loss-
es. Recent studies in our microcirculatory laboratory
suggest that some vasodilators have selective ef-
fects on the venular side of the capillary bed, and
preliminary evidence suggests that this may be the
main site for protein transfer. Nitroprusside, for ex-
ample, has dramatic effects on the venular side as
opposed to the arteriolar side of the capillary bed.
Therefore, all of the maneuvers that increase the
number of capillaries perfused may serve primarily
to increase the transfer of higher molecular weight
solutes by these area and permeability changes.
Yet, peritoneal dialysis usually provides clearances
of the larger solutes that are as high as or even high-
er than clearances achieved through hemodialysis
techniques. One could question, therefore, whether
the quest for new vasodilator techniques is really
going to accomplish anything useful. Instilling intra-
peritoneal vasodilating agents or administering oral
vasodilating agents usually increases the clearances
of the higher molecular weight solutes proportion-
ately more than the clearances of the lower molecu-
lar weight solutes. On the other hand, most perito-
neal diseases as well as hypoperfusion caused by
hypotension are associated with disproportionate
decreases in the clearance of higher molecular
weight solutes. The clearances of lower molecular
weight solutes remain remarkably stable when
vasoconstriction is induced and presumably the
number of capillaries perfused decreases as does
mean pore size. Thus, we can more easily manipu-
late the loss of protein and high molecular weight
solutes: What we would like to do is increase the
clearance of lower molecular weight solutes. I am
skeptical at this point that this can be done except
with very rapid dialysis solution cycling techniques
to minimize dialysate flow limitations and provide
better mixing. Even then urea clearances rarely ex-
ceed 30 to 40 mI/mm in humans [12]. We have re-
viewed possible reasons for limitations on urea
clearances elsewhere [12]. In brief, limited total
pore area—number of capillaries—, fluid films, and
poor mixing may all be involved. There is little evi-
dence to support limitations due to effective capil-
lary blood flow [12].
With vasodilators, urea clearances generally
show increases in the range of 5 to 10%—at the
most 15 to 20% [23]. On the other hand, inulin clear-
ance increases as much as 50 to 300%, as do protein
losses. The question becomes, Is one willing to
double protein losses for the sake of increasing
small solute clearances by less than 20%?
DR. J. T. HARRINGTON: Would you comment on
the efficiency of CAPD?
DR. K. D. NOLPH: Continuous ambulatory pen-
toneal dialysis takes an alternative approach to im-
proving the efficiency of peritoneal dialysis—name-
ly, operating at very low clearances but doing so
continuously. In this manner, total clearances of
urea per week can approach 75% of the weekly
clearance of urea on the standard hemodialysis regi-
men [20]. Another interesting advantage of CAPD is
that even if 80% of the peritoneum were destroyed,
approximately the same degree of control of BUN
would be possible because urea clearance would re-
main largely dependent on dialy sate flow rate. That
is, even with marked reduction in penitoneal surface
area, diffusion equilibrium can be achieved for urea
during the typical 4-hour dwell time used in CAPD,
and the same amount of urea will be removed.
Higher weight molecules such as inulin, however,
would have a reduced clearance proportional to the
reduction in peritoneal surface area—for example,
some 20% of the clearance of the intact peritoneum.
Nevertheless, because inulin clearances per week
on CAPD are about six times that with hemo-
dialysis, CAPD approaches the efficiency of hemo-
dialysis even at 20% of normal clearance. Thus,
CAPD does offer a way around the problem of low
clearances of small solutes in peritoneal dialysis.
Otherwise, the patient is faced with long hours of
intermittent penitoneal dialysis at very high flow
rates and even then the weekly urea clearances of
hemodialysis are not approached.
DR. J. J. COHEN: On your scale of small versus
large molecules, where does the middle molecule"
fall?
DR. K. D. NOLPH: The so-called middle molecule
usually refers to substances with molecular weights
in the range of 500 to 5,000 daltons [40]. The middle
molecule hypothesis actually stemmed from obser-
vations that patients treated with chronic peritoneal
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dialysis had a lower or no greater incidence of neu-
ropathy than those treated with hemodialysis [41—
45]. It seemed to follow that since the main dif-
ference between peritoneal and hemodialysis was
that peritoneal dialysis removed large solutes well
and small solutes poorly, neuropathy must be re-
lated to some higher molecular weight substance or
substances. At what molecular weight does perito-
neal dialysis become more efficient than hemo-
dialysis? It seems to depend on the peritoneal dialy-
sate flow rate. With the flow rates used in CAPD,
the break point is at approximately 1,000 daltons on
a weekly clearance basis [20].
DR. J. T. HARRINGTON: One important issue
raised by this patient is the difficulty in comparing
the effects of hemodialysis and peritoneal dialysis
even in the same individual. A major problem is the
fluctuating nature of the hemodynamic status in pa-
tients undergoing dialysis, illustrated in this woman
by the change in ejection fraction that occurred
over the period of observation. Does the Veterans
Administration study attempt to control for changes
in hemodynamic status?
DR. K. D. NOLPH: Obviously, there are many
variables within the study. The hemodialysis tech-
nique, for example, is not standardized; a variety of
techniques are permitted within the peritoneal dial-
ysis regimen as well, although all techniques are in-
termittent rather than continuous; a variety of types
of dialysis solutions and differences in approach are
permitted. All of these nonpatient-related variables
are important. The variables that I tried to point out
in connection with this patient are patient-related
variables. I tried to show how many different fac-
tors can affect a patient's tolerance of one technique
or another. In this patient, hemodialysis was very
poorly tolerated at one time in her course, but toler-
ated well at a later time. That compounds the prob-
lem. In the Veterans Administration study, the in-
tent is to overcome all of these variables by study-
ing the results in a large pool of patients from a large
number of centers. If there are distinct differences
between hemodialysis and peritoneal dialysis re-
garding control of serum chemistries, symptoms,
physical findings, and so on, it is felt they will
emerge even though many uncontrolled variables
are present. My major concern is that quantifiable
differences will not emerge. I suspect that there
may be more variables within the peritoneal dialysis
group and within the hemodialysis group than there
are between the two groups.
DR. E. TUTTLE: Do we know the size of this pa-
tient's heart? The change of ejection fraction from
40 to 60% may be the result of a reduction in the
end-diastolic volume because she was ultimately
unloaded. It would be useful to know whether this
improvement was the result of an improvement in
the physical anatomical state of the heart or wheth-
er it reflected improved myocardial contractility. I
would suspect that the major reason for the im-
provement was the reduction in fluid volume, which
diminished her preload. I think it would be inter-
esting to know this in assessing the change in her
hemodynamic response.
DR. J. T. HARRINGTON: I think that you are right,
Dr. Tuttle. Our assumption was that better volume
control was responsible for the improvement in car-
diac function.
DR. K. D. NOLPH: We have all seen improvement
in cardiac status through good volume control, and
I think that could have been a major factor in our
patient. One could also question whether autonom-
ic insufficiency due to urernic neuropathy played a
role, which raises again the possibility that perito-
neal dialysis, by removing middle molecules better,
might have reduced her uremic autonomic in-
sufficiency. Since we don't have firm evidence that
she had autonomic insufficiency, that is of course
only a speculative possibility.
DR. J. J. COHEN: If you had the full range of dial-
ysis techniques available to you, including CAPD,
and were faced with a patient over the age of 50
with diabetes and evident vascular disease, what
would your recommendation be concerning the
mode of dialysis to employ?
DR. K. D. NOLPU: I have great hopes that, with
the availability of peritoneal dialysis solutions in
sterile bags, we will be able to reduce the infection
rate in CAPD, rendering it more acceptable for use
in many patients. Continuous ambulatory perito-
neal dialysis has many advantages for the patient
with cardiovascular instability because with it there
are really no fluctuations at all in body fluid chem-
istries; they remain at a virtual steady state. Ultra-
filtration doesn't even have to be increased to the
level of that with intermittent peritoneal dialysis; it
goes on during each exchange four to five times dai-
ly. We have had several patients with diabetes who
underwent CAPD using the less satisfactory glass
bottle technique rather than sterile bags, and results
have been relatively satisfactory aside from the in-
fection problem. At this time, probably because I
am at a center that is evaluating CAPD, I think I
would be more than willing to consider a patient
such as this for it. Because of the problems of vas-
cular access and cardiovascular instability in pa-
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tients with diabetes, I am often asked to accept such
patients into the CAPD program.
Reprint requests to Dr. Karl Noiph, Division of Nephrology,
University of Missouri Medical Center, Columbia, Missouri
65201.
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